Free Trial
→ The chokepoint supplier behind SpaceX's $1.75 trillion empire (From Behind the Markets) (Ad)tc pixel Free FENC Stock Alerts

Adherex Technologies (FENC) Competitors

Adherex Technologies logo
$6.72 +0.07 (+1.05%)
Closing price 04:00 PM Eastern
Extended Trading
$6.72 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

FENC vs. SLS, XNCR, EVMN, TBPH, and JANX

Should you be buying Adherex Technologies stock or one of its competitors? The main competitors of Adherex Technologies include SELLAS Life Sciences Group (SLS), Xencor (XNCR), Evommune (EVMN), Theravance Biopharma (TBPH), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.

How does Adherex Technologies compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

SELLAS Life Sciences Group has a net margin of 0.00% compared to Adherex Technologies' net margin of -22.62%. SELLAS Life Sciences Group's return on equity of -63.06% beat Adherex Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
SELLAS Life Sciences GroupN/A -63.06% -54.50%
Adherex Technologies -22.62%-183.18%-15.31%

Adherex Technologies has higher revenue and earnings than SELLAS Life Sciences Group. Adherex Technologies is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SELLAS Life Sciences GroupN/AN/A-$26.86M-$0.25N/A
Adherex Technologies$44.64M5.20-$9.74M-$0.34N/A

SELLAS Life Sciences Group presently has a consensus target price of $10.00, indicating a potential upside of 105.34%. Adherex Technologies has a consensus target price of $14.80, indicating a potential upside of 120.24%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Adherex Technologies is more favorable than SELLAS Life Sciences Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SELLAS Life Sciences Group
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Adherex Technologies
2 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.57

17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 1.2% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 11.8% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Adherex Technologies had 2 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 6 mentions for Adherex Technologies and 4 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 0.72 beat Adherex Technologies' score of 0.33 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
SELLAS Life Sciences Group
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Adherex Technologies
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

SELLAS Life Sciences Group has a beta of 2.24, indicating that its stock price is 124% more volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.

Summary

Adherex Technologies beats SELLAS Life Sciences Group on 10 of the 16 factors compared between the two stocks.

How does Adherex Technologies compare to Xencor?

Xencor (NASDAQ:XNCR) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

55.5% of Adherex Technologies shares are owned by institutional investors. 4.8% of Xencor shares are owned by insiders. Comparatively, 11.8% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Adherex Technologies has a net margin of -22.62% compared to Xencor's net margin of -73.20%. Xencor's return on equity of -14.58% beat Adherex Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Xencor-73.20% -14.58% -10.42%
Adherex Technologies -22.62%-183.18%-15.31%

Adherex Technologies has lower revenue, but higher earnings than Xencor. Adherex Technologies is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xencor$125.58M7.59-$91.92M-$1.24N/A
Adherex Technologies$44.64M5.20-$9.74M-$0.34N/A

Xencor presently has a consensus target price of $24.38, suggesting a potential upside of 89.69%. Adherex Technologies has a consensus target price of $14.80, suggesting a potential upside of 120.24%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Adherex Technologies is more favorable than Xencor.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xencor
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.56
Adherex Technologies
2 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.57

Xencor has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.

In the previous week, Adherex Technologies had 2 more articles in the media than Xencor. MarketBeat recorded 6 mentions for Adherex Technologies and 4 mentions for Xencor. Xencor's average media sentiment score of 0.40 beat Adherex Technologies' score of 0.33 indicating that Xencor is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xencor
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Adherex Technologies
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Adherex Technologies beats Xencor on 9 of the 17 factors compared between the two stocks.

How does Adherex Technologies compare to Evommune?

Evommune (NYSE:EVMN) and Adherex Technologies (NASDAQ:FENC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

55.5% of Adherex Technologies shares are owned by institutional investors. 11.8% of Adherex Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Evommune has a net margin of 0.00% compared to Adherex Technologies' net margin of -22.62%. Evommune's return on equity of 0.00% beat Adherex Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
EvommuneN/A N/A N/A
Adherex Technologies -22.62%-183.18%-15.31%

Adherex Technologies has higher revenue and earnings than Evommune. Adherex Technologies is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evommune$13M66.98-$68.87M-$8.07N/A
Adherex Technologies$44.64M5.20-$9.74M-$0.34N/A

Evommune presently has a consensus target price of $49.13, suggesting a potential upside of 103.21%. Adherex Technologies has a consensus target price of $14.80, suggesting a potential upside of 120.24%. Given Adherex Technologies' higher possible upside, analysts plainly believe Adherex Technologies is more favorable than Evommune.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evommune
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
3 Strong Buy rating(s)
3.00
Adherex Technologies
2 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.57

In the previous week, Evommune and Evommune both had 6 articles in the media. Evommune's average media sentiment score of 0.61 beat Adherex Technologies' score of 0.33 indicating that Evommune is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evommune
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Adherex Technologies
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Evommune beats Adherex Technologies on 9 of the 15 factors compared between the two stocks.

How does Adherex Technologies compare to Theravance Biopharma?

Adherex Technologies (NASDAQ:FENC) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

Theravance Biopharma has a net margin of 98.54% compared to Adherex Technologies' net margin of -22.62%. Theravance Biopharma's return on equity of 16.76% beat Adherex Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Adherex Technologies-22.62% -183.18% -15.31%
Theravance Biopharma 98.54%16.76%9.23%

55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 11.8% of Adherex Technologies shares are held by company insiders. Comparatively, 6.9% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Adherex Technologies currently has a consensus target price of $14.80, suggesting a potential upside of 120.24%. Theravance Biopharma has a consensus target price of $21.83, suggesting a potential upside of 30.50%. Given Adherex Technologies' higher possible upside, analysts plainly believe Adherex Technologies is more favorable than Theravance Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adherex Technologies
2 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.57
Theravance Biopharma
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.75

In the previous week, Adherex Technologies had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 6 mentions for Adherex Technologies and 2 mentions for Theravance Biopharma. Adherex Technologies' average media sentiment score of 0.33 beat Theravance Biopharma's score of -0.09 indicating that Adherex Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adherex Technologies
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Theravance Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Theravance Biopharma has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adherex Technologies$44.64M5.20-$9.74M-$0.34N/A
Theravance Biopharma$107.46M8.02$105.89M$2.038.24

Adherex Technologies has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

Summary

Theravance Biopharma beats Adherex Technologies on 11 of the 17 factors compared between the two stocks.

How does Adherex Technologies compare to Janux Therapeutics?

Adherex Technologies (NASDAQ:FENC) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

Janux Therapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -22.62%. Janux Therapeutics' return on equity of -12.61% beat Adherex Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Adherex Technologies-22.62% -183.18% -15.31%
Janux Therapeutics N/A -12.61%-12.08%

55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 11.8% of Adherex Technologies shares are held by company insiders. Comparatively, 29.4% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Adherex Technologies currently has a consensus target price of $14.80, suggesting a potential upside of 120.24%. Janux Therapeutics has a consensus target price of $49.75, suggesting a potential upside of 247.17%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Janux Therapeutics is more favorable than Adherex Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adherex Technologies
2 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.57
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.60

In the previous week, Adherex Technologies had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 6 mentions for Adherex Technologies and 5 mentions for Janux Therapeutics. Adherex Technologies' average media sentiment score of 0.33 beat Janux Therapeutics' score of -0.03 indicating that Adherex Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adherex Technologies
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Janux Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Adherex Technologies has higher revenue and earnings than Janux Therapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adherex Technologies$44.64M5.20-$9.74M-$0.34N/A
Janux Therapeutics$10M87.36-$113.62M-$1.83N/A

Adherex Technologies has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.58, meaning that its stock price is 158% more volatile than the S&P 500.

Summary

Janux Therapeutics beats Adherex Technologies on 11 of the 16 factors compared between the two stocks.

Get Adherex Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FENC vs. The Competition

Export
MetricAdherex TechnologiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$232.12M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-19.7638.8529.0428.47
Price / Sales5.20155.51476.6160.92
Price / CashN/A57.8827.6236.52
Price / Book6.467.039.676.67
Net Income-$9.74M$23.62M$3.55B$332.53M
7 Day Performance0.30%3.68%1.70%2.01%
1 Month Performance4.67%7.16%5.62%9.19%
1 Year Performance7.01%67.05%34.41%39.59%

Adherex Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FENC
Adherex Technologies
3.6487 of 5 stars		$6.72
+1.1%		$14.80
+120.2%		N/A$232.12M$44.64MN/A10
SLS
SELLAS Life Sciences Group
1.3259 of 5 stars		$4.95
+6.0%		$10.00
+102.0%		N/A$861.77MN/AN/A10
XNCR
Xencor
2.4455 of 5 stars		$11.93
+2.7%		$24.38
+104.3%		N/A$861.36M$125.58MN/A280
EVMN
Evommune
N/A$23.73
-0.5%		$48.43
+104.1%		N/A$859.04M$13MN/A45
TBPH
Theravance Biopharma
3.2573 of 5 stars		$16.74
+0.4%		$21.83
+30.4%		N/A$858.76M$107.46M8.25110

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:FENC) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel